DR. LUIS PAZ ARES : " ES EL NACIMIENTO DE UNA NUEVA TERAPIA ”. TARLATAMAB TIENE EL POTENCIAL DE CAMBIAR EL MANEJO CLÍNICO DEL CÁNCER RECURRENTE/REFRACTARIO ( SEGUNDA LÍNEA ) Y MEJORAR LA SUPERVIVENCIA EN UN AÑO DE LOS PACIENTES CON SMALL_CELL_LUNG_CANCER .
DLL3-Targeted Drugs .
The Most Movel Therapies Right Now Are Those That Target DLL3 .
DLL3 IS a Receptor on The Surface of Many SMALL CELL LUNG CANCERS .
The Study That is Furthest Along As of The End of 2023 is a Drug Called TARLATAMAB, Which Binds DLL3 and Immune Cells Together, Creating an Immune Response that Enables The Immune System To Attack And Kill The Cáncer Cells . Like Other Immunotherapies, We’re Seeing a Subset of Individuals That Have Extraordinary Outcomes and Long-Term Disease Control With This Drug .
There Are Other Drugs in This Class in Addition To TARLATAMAB That Also Bind The Cáncer Cells And Immune Cells Together .
Antibody Drug Conjugates (ADCs) .
Other Drugs Now Being Developed Have a Different Target For The Immune Cell .
They Bring in a Different Kind of Cell From The Immune System Along With the Cáncer Cell to Create an Immune Response .
These Drugs Are Called Antibody Drug Conjugates (ADCs) .
We Are Essentially Accessing “ DOORS ” To SCLC To Be Able To Deliver Chemotherapy Into The Cells . ...